Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax

Total 81 results found. Search for [ NPPA ]

Results 60 to 80 of 81
Mumbai, September 23, 2014
The government has withdrawn guidelines issued on May 29 that gave the drug pricing regulator power to fix prices of drugs deemed non-essential.
New Delhi, September 20, 2014
Major drug companies, including Cipla, Ranbaxy, Lupin and Cadila, are likely to be impacted by the decision.
New Delhi/Mumbai, September 19, 2014
Drugmakers, including Cipla, Ranbaxy Laboratories, and Cadila Healthcare are among the companies that will be affected by the latest decision.
Hyderabad, August 11, 2014
According to Teva, it has received a Para-IV notice from the Indian drug maker over Copaxone, and the lawsuit may trigger a 30-month stay of FDA approval of Dr Reddy's Abbreviated New Drug Application.
New Delhi, July 30, 2014
Consolidated net sales of the company also rose to Rs 3,284 crore for the quarter under consideration as against Rs 2,420.7 crore for the same period a year ago.
New Delhi, July 24, 2014
The pricing anomaly has been caught by National Pharmaceutical Pricing Authority which has filed 22 cases this year alone, sending out demand notices that add up to Rs 221.78 crore.
July 15, 2014
\"By issuing a price control order under Para 19 without any consultation with the industry bodies, the NPPA has shocked and disappointed the pharma industry,\" said Shailesh Ayyangar, Managing Director India and Vice-President (South Asia), Sanofi India Limited, one of the companies likely to be affected by this move.
July 14, 2014
India last year raised the number of drugs that are subject to price controls to cover up to 30 per cent of the total medication sold in the country, according to industry officials.
April 29, 2014
Cipla, whose chairman Yusuf Khwaja Hamied, jolted the global pharma industry in 2001 with his offer to sell anti-AIDS drugs at less than 4 per cent of the price charged by international drugmakers, in January this year got a notice for overcharging for some medicines in India.
New Delhi, August 5, 2013
Seven more pharmaceutical companies including Novartis India Limited on Monday moved the Delhi High Court to challenge the government's new drug pricing order that asked them to slash prices of 348 medicines.
New Delhi, July 27, 2013
The Delhi High Court asked the Centre not to take coercive steps against pharma major Cipla Ltd which has challenged a government order asking it to reduce prices of its 125 drugs within 45 days of issuance of the notification.
July 8, 2013
Analysts expect the Indian sales of most pharma companies to be adversely affected in the current quarter, as local distributors are not likely to pick up stocks since the new drug policy will take effect next quarter.
New Delhi, June 18, 2013
The drug pricing regulator will fix the ceiling prices of over 300 medicines by the end of this month, a move that will come as a major relief to patients.
New Delhi, May 17, 2013
The Department of Pharmaceuticals has notified the Drugs (Prices Control) Order 2013, under which prices of 348 medicines have been brought under price control.
New Delhi, May 16, 2013
Prices of 348 medicines, including life saving drugs, will be cheaper soon by up to 80 per cent as the new Drug Price Control Order has come into effect.
New Delhi, December 13, 2012
The National Pharmaceutical Pricing Policy 2012, which was cleared by the government in November, would bring 348 essential drugs under price control.
New Delhi, November 22, 2012
The National Pharmaceutical Pricing Policy has been approved by the Cabinet with an objective to put in place a regulatory framework for pricing of drugs to ensure their availability at reasonable prices.
New Delhi, October 26, 2012
Despite the National Pharmaceutical Pricing Authority imposing fines on pharmaceutical companies several times for overpricing of drugs in the last 17 years, these firms are unrelenting and continue to charge high prices from consumers.
New Delhi, March 17, 2011
The pharmaceutical pricing authority said raw material costs and revision in the norms of conversion cost justified the hike. Majority of these drugs treat diabetics.
New Delhi, December 28, 2010
Drug firm Cipla on Tuesday said it has received fresh notices from National Pharmaceutical Pricing Authority (NPPA) for Rs 73.16 crore for overpricing of two drugs.

PAGES 4 OF 5  12345